Learned immunosuppressive placebo responses in renal transplant patients.
Julia Kirchhof, Liubov Petrakova, Alexandra Brinkhoff...
https://pubmed.ncbi.nlm.nih.gov/29610294/Actively Recruiting
Led by University of California, San Francisco · Updated on 2026-03-13
64
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the effects of adding an open-label placebo COLP to the usual postoperative treatment for adolescents aged 10 to 18 undergoing surgery for idiopathic scoliosis. This randomized controlled trial will involve 64 patients divided into two groups to compare opioid consumption and other clinical outcomes over 6 weeks following surgery. The study also examines associations between pain perception, anxiety, depression, and response to the treatments. Participants will be randomly assigned to either receive open-label placebo tablets along with standard treatment or standard treatment alone. The placebo is a 330mg tablet taken with each opioid dose and three additional times daily, starting the day after surgery. Standard treatment includes opioid analgesics 5mg Oxycodone tablets and Tylenol, with specific restrictions on other medications. The trial will last 6 weeks with detailed monitoring. Throughout the study, clinical data will be collected at regular clinic visits, including patient surveys using PROMIS scales to assess mobility, anxiety, and depressive symptoms. Researchers will track opioid use, physical therapy independence, hospital stay length, return to school time, and side effects such as urinary retention, constipation, and oxygen needs. The total participation period covers from hospital admission to 6 weeks post-surgery, with close monitoring of recovery and medication use.
CONDITIONS
Open-label Placebo (COLP) for Pain in Adolescent Idiopathic Scoliosis (AIS) Surgery+Surgical Treatment of Idiopathic Scoliosis
M
Mohammad Diab, MD
T
Tripta Rughwani
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, San Francisco
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Open-label Placebo (COLP) with Usual Pain Management | Treatment as Usual (TAU) |
|---|---|---|
| What it is | Open-label placebo (a 330mg tablet) given transparently to patients alongside each opioid dose and three extra times daily after surgery. All participants also receive scheduled acetaminophen, as per the usual post-operative pain protocol. | Post-operative pain management using oral opioid (5mg oxycodone as needed) and scheduled acetaminophen (625mg every 8 hours) without placebo tablets. Ibuprofen is not prescribed. |
| Role in study | Assesses whether adding open-label placebo to standard pain treatment can reduce opioid use or improve recovery after adolescent spine surgery. | Represents standard post-operative pain management in pediatric scoliosis surgery, serving as the control condition for comparison. |
| Primary clinical use | Tested to determine if a knowingly administered placebo can help manage post-surgical pain and decrease the amount of opioid required in recovering adolescents. | Used for the relief of post-operative pain following spine surgery in adolescents, aiming to maintain comfort while supporting physical recovery. |
| How it is given or performed | A 330mg placebo tablet is taken with every oral opioid dose, and three additional tablets are taken throughout the day, starting on the first day after surgery. All participants receive scheduled acetaminophen and opioids as needed based on standard practice. | Opioid tablets (5mg oxycodone) are given as needed for pain, along with acetaminophen (625mg) every 8 hours. Placebo tablets are not provided. |
| Evidence status | There is emerging but limited evidence from adult and some pediatric studies suggesting open-label placebo may reduce pain and opioid use. Its benefit after adolescent spine surgery is not yet established; this trial aims to directly address that question. | Standard opioid-based regimens combined with scheduled acetaminophen are widely used and effective for post-operative pain control in adolescent scoliosis surgery. |
| Important limitations | Effectiveness of open-label placebo for reducing post-surgical pain or opioid need in adolescents is not yet confirmed; available data are primarily from adult or non-surgical populations. The intervention does not replace standard pain medications. | Opioid-based regimens may be associated with known risks such as nausea, constipation, and risk of dependence. Ibuprofen is intentionally not prescribed in this protocol, which may be a deviation from some institutional practices. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Hospital stay up to 6 weeks post-surgery
Participants undergo surgery for idiopathic scoliosis and begin immediate post-operative care including opioid and non-opioid pain management.
Daily hospital visits during stay
Duration - 6 weeks post-operatively
Participants receive either open-label placebo tablets along with standardized opioid treatment or treatment as usual with opioid and non-opioid analgesics for pain management after surgery.
Weekly visits for up to 6 weeks
Duration - Up to 6 weeks post-operatively
Participants are monitored for recovery outcomes including mobility, anxiety, depression, opioid consumption, physical therapy independence, and return to school.
Weekly assessments for up to 6 weeks
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Julia Kirchhof, Liubov Petrakova, Alexandra Brinkhoff...
https://pubmed.ncbi.nlm.nih.gov/29610294/Cláudia Carvalho, Joaquim Machado Caetano, Lidia Cunha...
https://pubmed.ncbi.nlm.nih.gov/27755279/Samuel Nurko, Miguel Saps, Joe Kossowsky...
https://pubmed.ncbi.nlm.nih.gov/35099543/Kelsey M Flowers, Megan E Patton, Valerie J Hruschak...
https://pubmed.ncbi.nlm.nih.gov/33449503/Melina von Wernsdorff, Martin Loef, Brunna Tuschen-Caffier...
https://pubmed.ncbi.nlm.nih.gov/33594150/Adrian D Sandler, Corrine E Glesne, James W Bodfish
https://pubmed.ncbi.nlm.nih.gov/20495473/Robert Ader, Mary Gail Mercurio, James Walton...
https://pubmed.ncbi.nlm.nih.gov/20028830/Bettina K Doering, Winfried Rief
https://pubmed.ncbi.nlm.nih.gov/22284159/Charlotte Blease, Luana Colloca, Ted J Kaptchuk
https://pubmed.ncbi.nlm.nih.gov/26840547/Kira S Furie, Kaitlyn James, Ted J Kaptchuk...
https://pubmed.ncbi.nlm.nih.gov/40536435/University of California, San Francisco
Lead Sponsor